Immunome, Inc. Announces Successful Pricing of Public Offering

Immunome, Inc. (NASDAQ: IMNM) disclosed in a recent 8-K filing that they have entered into an underwriting agreement on January 29, 2025, with key underwriters, including J.P. Morgan Securities LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Guggenheim Securities, LLC. This agreement involves the issuance and sale of 19,354,839 shares of Immunome’s common stock at a price of $7.75 per share in a public offering. The total gross proceeds from this offering are estimated to be $150.0 million.

The offering, anticipated to close on January 31, 2025, is contingent upon the completion of standard closing conditions. Additionally, Immunome has granted the Underwriters a 30-day option to purchase up to an additional 2,903,225 shares of Common Stock at the public offering price, less underwriting discounts and commissions.

Within the agreement, customary representations, warranties, and agreements have been established, along with indemnification obligations and termination provisions. The offered shares are part of a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2024.

Immunome also revealed that two press releases were issued on January 29, 2025, discussing the commencement and pricing of the offering. The company shared that the offering is forward-looking and is subject to market conditions and customary closing conditions. Risks and uncertainties associated with the offering have been detailed in their filings with the SEC.

The offering signifies Immunome’s commitment to advancing innovative cancer therapeutics. The company is dedicated to developing targeted therapies that enhance outcomes for cancer patients, with ongoing programs in various stages of development, including varegacestat, IM-1021, and IM-3050.

Investors seeking further details about the offering can refer to the official SEC filings and prospectus. Immunome has emphasized that market conditions and closing conditions are pivotal factors affecting the ultimate realization of the offering.

For any inquiries, individuals can reach out to Max Rosett, Chief Financial Officer, at [email protected].

This news article is based on the formal 8-K filing submitted to the Securities and Exchange Commission by Immunome, Inc., and does not contain any subjective opinions or additional information beyond the disclosed facts.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Immunome’s 8K filing here.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.